ADAPY — Adaptimmune Therapeutics PLC
—
·
Health Care ·
Biotechnology ·
CIK 1621227 ·
United Kingdom
Last close
$0.03
Market Cap
—
52W High
$0.05
52W Low
$0.00
ADV30
447,215
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 13,677,000 | 11,176,000 | -29,717,000 | -30,340,000 | 130,633,000 | 26,061,000 | 201,591,000 |
| Mar 2025 | 7,285,000 | 6,406,000 | -44,071,000 | -47,584,000 | 158,072,000 | 41,054,000 | 195,501,000 |
| Dec 2024 | 3,222,000 | — | -57,168,000 | -74,215,000 | 245,963,000 | 91,139,000 | 234,114,000 |
| Sep 2024 | 40,901,000 | — | -14,680,000 | -17,617,000 | 317,436,000 | 116,741,000 | 237,447,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-190,027,000
Investing CF
$1,793,000
Financing CF
$1,336,000
CapEx
$-2,886,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.36
As of
2026-06-14
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,171,911,000
Inventory
$11,411,000
Receivables
$28,895,000
ST Investments
$0
EBIT TTM
$-160,380,000
Pretax Income TTM
$-166,045,000
Interest Exp TTM
$5,665,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 178,032,000 | -52,409,000 | -70,814,000 | 245,963,000 | 234,114,000 | — | -73,206,000 |
| Dec 2023 | 60,281,000 | -138,038,000 | -113,871,000 | 282,616,000 | 243,103,000 | — | -140,880,000 |
| Dec 2022 | 27,148,000 | -163,965,000 | -165,456,000 | 328,916,000 | 247,038,000 | — | -141,769,000 |
| Dec 2021 | 6,149,000 | -162,246,000 | -158,090,000 | 469,545,000 | 263,585,000 | — | 10,729,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $209.21B | $387.64 | — |
| GILD | GILEAD SCIENCES, INC. | $164.79B | $132.73 | — |
| ARGX | ARGENX SE | $55.21B | $882.56 | — |
| RVMD | Revolution Medicines, Inc. | $38.46B | $180.92 | — |
| BIIB | BIOGEN INC. | $30.91B | $209.23 | — |
News headlines (Yahoo Finance, 1h cache)
How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak
2026-07-27 15:54 · Yahoo
Flagship Pioneering Appoints Adrian Rawcliffe as CEO-Partner and CEO of Etiome
2026-01-08 13:00 · Yahoo
Adaptimmune Announces Changes to Board and Executive Leadership Team
2025-11-17 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.